Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PRMT7-WWOX

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PRMT7-WWOX
	FusionPDB ID: 68942
	FusionGDB2.0 ID: 68942
		Hgene	Tgene
	Gene symbol	PRMT7	WWOX
	Gene ID	54496	51741
	Gene name	protein arginine methyltransferase 7	WW domain containing oxidoreductase
	Synonyms	SBIDDS	D16S432E\|EIEE28\|FOR\|FRA16D\|HHCMA56\|PRO0128\|SCAR12\|SDR41C1\|WOX1
	Cytomap	16q22.1	16q23.1-q23.2
	Type of gene	protein-coding	protein-coding
	Description	protein arginine N-methyltransferase 7[Myelin basic protein]-arginine N-methyltransferase PRMT7histone-arginine N-methyltransferase PRMT7	WW domain-containing oxidoreductaseWW domain-containing protein WWOXfragile site FRA16D oxidoreductaseshort chain dehydrogenase/reductase family 41C member 1
	Modification date	20200320	20200313
	UniProtAcc	.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000339507, ENST00000348497, ENST00000441236, ENST00000449359, ENST00000564441,	ENST00000355860, ENST00000402655, ENST00000406884, ENST00000408984, ENST00000539474, ENST00000565791, ENST00000569818, ENST00000566780,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	4 X 5 X 4=80	30 X 23 X 10=6900
	# samples	4	36
	** MAII score	log2(4/80*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(36/6900*10)=-4.26052755022322 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PRMT7 [Title/Abstract] AND WWOX [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PRMT7 [Title/Abstract] AND WWOX [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PRMT7(68382334)-WWOX(78420757), # samples:1 PRMT7(68380183)-WWOX(78420757), # samples:1
Anticipated loss of major functional domain due to fusion event.	PRMT7-WWOX seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRMT7-WWOX seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRMT7-WWOX seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PRMT7-WWOX seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	PRMT7	GO:0016571	histone methylation	15494416
Hgene	PRMT7	GO:0018216	peptidyl-arginine methylation	15044439
Tgene	WWOX	GO:0030178	negative regulation of Wnt signaling pathway	19465938
Tgene	WWOX	GO:0071560	cellular response to transforming growth factor beta stimulus	19366691

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:68382334/chr16:78420757)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PRMT7 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across WWOX (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000449359	PRMT7	chr16	68382334	+	ENST00000566780	WWOX	chr16	78420757	+	2990	1390	61	2118	685
ENST00000441236	PRMT7	chr16	68382334	+	ENST00000566780	WWOX	chr16	78420757	+	3695	2095	766	2823	685
ENST00000339507	PRMT7	chr16	68382334	+	ENST00000566780	WWOX	chr16	78420757	+	3843	2243	764	2971	735
ENST00000449359	PRMT7	chr16	68380183	+	ENST00000566780	WWOX	chr16	78420757	+	2768	1168	61	1896	611
ENST00000441236	PRMT7	chr16	68380183	+	ENST00000566780	WWOX	chr16	78420757	+	3473	1873	766	2601	611
ENST00000348497	PRMT7	chr16	68380183	+	ENST00000566780	WWOX	chr16	78420757	+	3401	1801	766	2529	587
ENST00000339507	PRMT7	chr16	68380183	+	ENST00000566780	WWOX	chr16	78420757	+	3621	2021	764	2749	661

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000449359	ENST00000566780	PRMT7	chr16	68382334	+	WWOX	chr16	78420757	+	0.005876144	0.9941239
ENST00000441236	ENST00000566780	PRMT7	chr16	68382334	+	WWOX	chr16	78420757	+	0.006140051	0.9938599
ENST00000339507	ENST00000566780	PRMT7	chr16	68382334	+	WWOX	chr16	78420757	+	0.005588749	0.9944113
ENST00000449359	ENST00000566780	PRMT7	chr16	68380183	+	WWOX	chr16	78420757	+	0.007901163	0.9920988
ENST00000441236	ENST00000566780	PRMT7	chr16	68380183	+	WWOX	chr16	78420757	+	0.00829893	0.99170107
ENST00000348497	ENST00000566780	PRMT7	chr16	68380183	+	WWOX	chr16	78420757	+	0.007908159	0.9920919
ENST00000339507	ENST00000566780	PRMT7	chr16	68380183	+	WWOX	chr16	78420757	+	0.007667402	0.9923326

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PRMT7-WWOX

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
PRMT7	chr16	68380183	WWOX	chr16	78420757	1168	369	QDRTDRYVQALRTHKAKVEAMTLDLA
PRMT7	chr16	68380183	WWOX	chr16	78420757	1801	345	QDRTDRYVQALRTHKAKVEAMTLDLA
PRMT7	chr16	68380183	WWOX	chr16	78420757	1873	369	QDRTDRYVQALRTHKAKVEAMTLDLA
PRMT7	chr16	68380183	WWOX	chr16	78420757	2021	419	QDRTDRYVQALRTHKAKVEAMTLDLA
PRMT7	chr16	68382334	WWOX	chr16	78420757	1390	443	PELLTNEDLQGRKHKAKVEAMTLDLA
PRMT7	chr16	68382334	WWOX	chr16	78420757	2095	443	PELLTNEDLQGRKHKAKVEAMTLDLA
PRMT7	chr16	68382334	WWOX	chr16	78420757	2243	493	PELLTNEDLQGRKHKAKVEAMTLDLA

Top

Potential FusionNeoAntigen Information of PRMT7-WWOX in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

PRMT7-WWOX_68380183_78420757.msa
PRMT7-WWOX_68382334_78420757.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B39:06	THKAKVEA	0.9992	0.8255	12	20
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-A30:08	RTHKAKVEA	0.9965	0.673	11	20
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B39:01	THKAKVEAM	0.9943	0.8425	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B39:06	THKAKVEAM	0.9908	0.7929	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B14:02	THKAKVEAM	0.969	0.6714	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B14:01	THKAKVEAM	0.969	0.6714	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B38:01	THKAKVEAM	0.9639	0.9256	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B38:02	THKAKVEAM	0.9634	0.924	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B15:10	THKAKVEAM	0.9529	0.5945	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B15:18	THKAKVEAM	0.8594	0.8069	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B15:37	THKAKVEAM	0.6543	0.6112	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-A30:08	RYVQALRTHK	0.973	0.604	5	15
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B15:10	THKAKVEAMTL	0.9913	0.622	12	23
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B15:37	THKAKVEAMTL	0.9815	0.6152	12	23
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B39:09	THKAKVEAM	0.9961	0.6521	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B39:12	THKAKVEAM	0.994	0.8449	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B39:05	THKAKVEAM	0.9644	0.8329	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-C07:13	THKAKVEAM	0.6874	0.8891	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-C07:29	THKAKVEAM	0.6842	0.8803	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-C07:46	THKAKVEAM	0.6179	0.9116	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-C07:80	THKAKVEAM	0.5701	0.95	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-C07:67	THKAKVEAM	0.5701	0.95	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-C07:10	THKAKVEAM	0.5395	0.9722	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B14:03	THKAKVEAM	0.5196	0.7388	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B15:04	VQALRTHKA	0.3326	0.8688	7	16
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-C12:16	THKAKVEAM	0.1021	0.9313	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-C07:46	RYVQALRTH	0.0405	0.9287	5	14
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-A30:01	RTHKAKVEA	0.9967	0.8119	11	20
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B39:02	THKAKVEAM	0.9942	0.916	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B39:31	THKAKVEAM	0.9891	0.8418	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-A30:01	YVQALRTHK	0.986	0.6632	6	15
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-A02:03	ALRTHKAKV	0.9696	0.7012	9	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B38:05	THKAKVEAM	0.9639	0.9256	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B15:09	THKAKVEAM	0.8243	0.8729	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B39:11	THKAKVEAM	0.6632	0.5416	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-C07:02	THKAKVEAM	0.5701	0.95	12	21
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-A30:01	RYVQALRTHK	0.9742	0.7358	5	15
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	HLA-B15:09	THKAKVEAMTL	0.9778	0.8471	12	23
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B39:01	KHKAKVEAM	0.9694	0.8297	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B18:01	NEDLQGRKH	0.8193	0.8375	5	14
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B38:02	KHKAKVEAM	0.7695	0.9176	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B14:02	KHKAKVEAM	0.7541	0.6961	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B14:01	KHKAKVEAM	0.7541	0.6961	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B15:18	KHKAKVEAM	0.4854	0.7585	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B15:03	KHKAKVEAM	0.4549	0.7893	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B15:10	KHKAKVEAM	0.4437	0.5753	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B15:37	KHKAKVEAM	0.0659	0.6279	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B39:09	KHKAKVEAM	0.9714	0.5577	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B39:12	KHKAKVEAM	0.9698	0.834	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-C07:29	KHKAKVEAM	0.7781	0.8906	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-C07:13	KHKAKVEAM	0.769	0.8827	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B39:05	KHKAKVEAM	0.7641	0.8079	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-C07:46	KHKAKVEAM	0.6676	0.891	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B14:03	KHKAKVEAM	0.355	0.631	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B39:31	KHKAKVEAM	0.9243	0.8299	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B18:05	NEDLQGRKH	0.8193	0.8375	5	14
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B18:06	NEDLQGRKH	0.7376	0.8426	5	14
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B18:11	NEDLQGRKH	0.5787	0.7623	5	14
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B15:68	KHKAKVEAM	0.4386	0.6777	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B39:11	KHKAKVEAM	0.1758	0.578	12	21
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	HLA-B15:09	KHKAKVEAM	0.1018	0.7491	12	21

Top

Potential FusionNeoAntigen Information of PRMT7-WWOX in HLA II

PRMT7-WWOX_68380183_78420757.msa
PRMT7-WWOX_68382334_78420757.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0102	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0102	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0103	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0103	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0109	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0115	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0123	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0123	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0123	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0123	RYVQALRTHKAKVEA	5	20
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0415	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0415	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0415	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0436	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0436	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0436	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0437	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0437	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0437	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0437	RYVQALRTHKAKVEA	5	20
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0447	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0453	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0453	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0458	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0458	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0458	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0473	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-0473	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1002	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1002	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1172	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1172	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1204	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1204	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1209	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1209	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1213	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1215	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1218	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1219	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1220	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1220	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1221	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1221	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1223	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1326	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1385	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1385	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1386	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1403	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1403	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1440	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1440	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1451	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1457	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1457	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1467	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1467	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1477	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1477	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1498	TDRYVQALRTHKAKV	3	18
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1498	RTDRYVQALRTHKAK	2	17
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB1-1615	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68380183	chr16	78420757	2021	DRB5-0204	DRYVQALRTHKAKVE	4	19
PRMT7-WWOX	chr16	68382334	chr16	78420757	2243	DRB1-0422	PELLTNEDLQGRKHK	0	15

Top

Fusion breakpoint peptide structures of PRMT7-WWOX

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
1602	EDLQGRKHKAKVEA	PRMT7	WWOX	chr16	68382334	chr16	78420757	2243

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
10849	YVQALRTHKAKVEA	PRMT7	WWOX	chr16	68380183	chr16	78420757	2021

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PRMT7-WWOX

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	1602	EDLQGRKHKAKVEA	-7.9962	-8.1096
HLA-B14:02	3BVN	1602	EDLQGRKHKAKVEA	-5.70842	-6.74372
HLA-B52:01	3W39	1602	EDLQGRKHKAKVEA	-6.83737	-6.95077
HLA-B52:01	3W39	1602	EDLQGRKHKAKVEA	-4.4836	-5.5189
HLA-A11:01	4UQ2	1602	EDLQGRKHKAKVEA	-10.0067	-10.1201
HLA-A11:01	4UQ2	1602	EDLQGRKHKAKVEA	-9.03915	-10.0745
HLA-A24:02	5HGA	1602	EDLQGRKHKAKVEA	-6.56204	-6.67544
HLA-A24:02	5HGA	1602	EDLQGRKHKAKVEA	-5.42271	-6.45801
HLA-B44:05	3DX8	1602	EDLQGRKHKAKVEA	-7.85648	-8.89178
HLA-B44:05	3DX8	1602	EDLQGRKHKAKVEA	-5.3978	-5.5112
HLA-A02:01	6TDR	1602	EDLQGRKHKAKVEA	-3.37154	-4.40684
HLA-B14:02	3BVN	10849	YVQALRTHKAKVEA	-7.9962	-8.1096
HLA-B14:02	3BVN	10849	YVQALRTHKAKVEA	-5.70842	-6.74372
HLA-B52:01	3W39	10849	YVQALRTHKAKVEA	-6.83737	-6.95077
HLA-B52:01	3W39	10849	YVQALRTHKAKVEA	-4.4836	-5.5189
HLA-A11:01	4UQ2	10849	YVQALRTHKAKVEA	-10.0067	-10.1201
HLA-A11:01	4UQ2	10849	YVQALRTHKAKVEA	-9.03915	-10.0745
HLA-A24:02	5HGA	10849	YVQALRTHKAKVEA	-6.56204	-6.67544
HLA-A24:02	5HGA	10849	YVQALRTHKAKVEA	-5.42271	-6.45801
HLA-B44:05	3DX8	10849	YVQALRTHKAKVEA	-7.85648	-8.89178
HLA-B44:05	3DX8	10849	YVQALRTHKAKVEA	-5.3978	-5.5112
HLA-A02:01	6TDR	10849	YVQALRTHKAKVEA	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of PRMT7-WWOX

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
PRMT7-WWOX	chr16	68380183	chr16	78420757	11	20	RTHKAKVEA	AGGACCCATAAAGCCAAGGTAGAAGCA
PRMT7-WWOX	chr16	68380183	chr16	78420757	12	20	THKAKVEA	ACCCATAAAGCCAAGGTAGAAGCA
PRMT7-WWOX	chr16	68380183	chr16	78420757	12	21	THKAKVEAM	ACCCATAAAGCCAAGGTAGAAGCAATG
PRMT7-WWOX	chr16	68380183	chr16	78420757	12	23	THKAKVEAMTL	ACCCATAAAGCCAAGGTAGAAGCAATGACCCTG
PRMT7-WWOX	chr16	68380183	chr16	78420757	5	14	RYVQALRTH	CGATACGTCCAGGCTCTGAGGACCCAT
PRMT7-WWOX	chr16	68380183	chr16	78420757	5	15	RYVQALRTHK	CGATACGTCCAGGCTCTGAGGACCCATAAA
PRMT7-WWOX	chr16	68380183	chr16	78420757	6	15	YVQALRTHK	TACGTCCAGGCTCTGAGGACCCATAAA
PRMT7-WWOX	chr16	68380183	chr16	78420757	7	16	VQALRTHKA	GTCCAGGCTCTGAGGACCCATAAAGCC
PRMT7-WWOX	chr16	68380183	chr16	78420757	9	18	ALRTHKAKV	GCTCTGAGGACCCATAAAGCCAAGGTA
PRMT7-WWOX	chr16	68382334	chr16	78420757	12	21	KHKAKVEAM	AAGCATAAAGCCAAGGTAGAAGCAATG
PRMT7-WWOX	chr16	68382334	chr16	78420757	5	14	NEDLQGRKH	AATGAGGACCTACAGGGCAGAAAGCAT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
PRMT7-WWOX	chr16	68380183	chr16	78420757	2	17	RTDRYVQALRTHKAK	AGAACTGATCGATACGTCCAGGCTCTGAGGACCCATAAAGCCAAG
PRMT7-WWOX	chr16	68380183	chr16	78420757	3	18	TDRYVQALRTHKAKV	ACTGATCGATACGTCCAGGCTCTGAGGACCCATAAAGCCAAGGTA
PRMT7-WWOX	chr16	68380183	chr16	78420757	4	19	DRYVQALRTHKAKVE	GATCGATACGTCCAGGCTCTGAGGACCCATAAAGCCAAGGTAGAA
PRMT7-WWOX	chr16	68380183	chr16	78420757	5	20	RYVQALRTHKAKVEA	CGATACGTCCAGGCTCTGAGGACCCATAAAGCCAAGGTAGAAGCA
PRMT7-WWOX	chr16	68382334	chr16	78420757	0	15	PELLTNEDLQGRKHK	CCGGAATTATTAACAAATGAGGACCTACAGGGCAGAAAGCATAAA

Top

Information of the samples that have these potential fusion neoantigens of PRMT7-WWOX

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
STAD	PRMT7-WWOX	chr16	68380183	ENST00000339507	chr16	78420757	ENST00000566780	TCGA-BR-A4QI-01A
STAD	PRMT7-WWOX	chr16	68382334	ENST00000339507	chr16	78420757	ENST00000566780	TCGA-BR-A4QI-01A

Top

Potential target of CAR-T therapy development for PRMT7-WWOX

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PRMT7-WWOX

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PRMT7-WWOX

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)